In vivo investigations revealed that OSS_128167 administration or shSirt6 transfection mediated Sirt6 downregulation, both resulted in inhibition of tumor growth in xenograft models of DLBCL. This evidence concerns the gene SIRT6 and diffuse large B-cell lymphoma.